Dr. Fisher receives R37 Merit Award from the National Cancer Institute

Patients with metastatic chemotherapy have a 5 year survival rate of 14% with is exacerbated by K-Ras mutations.  Previous work by Dr. Fisher and his team have shown that K-Ras muations increase the transcriptional co-activator PGC-1-b. Thus the goal of this application is to develop novel therapies for metastatic disease that inhibit PGC-1-b. No current, similar treatments have been developed.  The Method to Extend Research in Time (MERIT)(R37) Award provides longer term grant support to Early Stage Investigators and is awarded by the Program Officer/Council.  Awardees may obtain up to seven years of support in two segments:  an initial award of up to five years and an opportunity for an extension of up to two additional years, based on an expedited NCI review of the accomplishments during the initial funding segment.  Congratulations to Dr. Fisher!